Lv12
24 积分 2024-11-12 加入
WED-371 Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment
1小时前
求助中
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
1小时前
已完结
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
2小时前
已完结
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
3小时前
已完结
Exogenous RNA surveillance by proton-sensing TRIM25
1个月前
已完结
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AM
1个月前
已完结
Neoantigens in cancer immunotherapy
2个月前
已完结
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy
2个月前
已完结
Induction of Bystander T Cell Proliferation by Viruses and Type I Interferon in Vivo
2个月前
已完结
Overcoming resistance in oncolytic virotherapy: Nano-engineered solutions for systemic delivery and efficacy boost
3个月前
已完结
皖公网安备34019202002308
